Corvus Pharmaceuticals (CRVS) Other Accumulated Expenses (2015 - 2026)

Corvus Pharmaceuticals' Other Accumulated Expenses history runs 12 years deep, the most recent figure standing at $206000.0 for Q1 2026.

• On a quarterly basis, Other Accumulated Expenses fell 30.41% year-over-year to $206000.0 in Q1 2026; TTM through Mar 2026 was $206000.0, a 30.41% decrease from a year earlier, with the FY2025 full-year figure at $238000.0, down 17.65% from the prior year.
• Other Accumulated Expenses eased to $206000.0 in Q1 2026 per CRVS's latest filing, from $238000.0 in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $566000.0 in Q3 2025 and bottomed at $131000.0 in Q2 2022.
• The 5-year median for Other Accumulated Expenses is $238000.0 (2025), against an average of $261411.8.
• Across the five-year window, Other Accumulated Expenses tumbled 66.78% in 2022 and soared 85.78% in 2023, its largest moves.
• Year by year, Other Accumulated Expenses stood at $158000.0 in 2022, then surged by 55.06% to $245000.0 in 2023, then climbed by 17.96% to $289000.0 in 2024, then decreased by 17.65% to $238000.0 in 2025, then declined by 13.45% to $206000.0 in 2026.
• Per Business Quant, the three latest CRVS Other Accumulated Expenses figures stand at $206000.0 (Q1 2026), $238000.0 (Q4 2025), and $566000.0 (Q3 2025).